[go: up one dir, main page]

DK1026950T3 - Behandling af skizofreni med ampakiner og neuroleptika - Google Patents

Behandling af skizofreni med ampakiner og neuroleptika

Info

Publication number
DK1026950T3
DK1026950T3 DK98957382T DK98957382T DK1026950T3 DK 1026950 T3 DK1026950 T3 DK 1026950T3 DK 98957382 T DK98957382 T DK 98957382T DK 98957382 T DK98957382 T DK 98957382T DK 1026950 T3 DK1026950 T3 DK 1026950T3
Authority
DK
Denmark
Prior art keywords
schizophrenia
treatment
ampakines
neuroleptics
relates
Prior art date
Application number
DK98957382T
Other languages
Danish (da)
English (en)
Inventor
Steven A Johnson
Gary A Rogers
Gary S Lynch
Original Assignee
Univ California
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22050462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1026950(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Cortex Pharma Inc filed Critical Univ California
Application granted granted Critical
Publication of DK1026950T3 publication Critical patent/DK1026950T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98957382T 1997-10-27 1998-10-26 Behandling af skizofreni med ampakiner og neuroleptika DK1026950T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6362797P 1997-10-27 1997-10-27

Publications (1)

Publication Number Publication Date
DK1026950T3 true DK1026950T3 (da) 2006-06-26

Family

ID=22050462

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98957382T DK1026950T3 (da) 1997-10-27 1998-10-26 Behandling af skizofreni med ampakiner og neuroleptika

Country Status (14)

Country Link
US (1) US6166008A (es)
EP (1) EP1026950B1 (es)
JP (1) JP2001520978A (es)
CN (1) CN1281335A (es)
AT (1) ATE317226T1 (es)
AU (1) AU745641B2 (es)
BR (1) BR9814106A (es)
CA (1) CA2306817A1 (es)
CY (1) CY1105557T1 (es)
DE (1) DE69833451T2 (es)
DK (1) DK1026950T3 (es)
ES (1) ES2258825T3 (es)
PT (1) PT1026950E (es)
WO (1) WO1999021422A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2138533C (en) 1992-07-24 2009-04-14 Gary S. Lynch Drugs that enhance synaptic responses mediated by ampa receptors
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
US20050020582A1 (en) * 2001-05-25 2005-01-27 Prusiner Stanley B Optically active compounds clearing malformed proteins
US20040229898A1 (en) * 2001-05-25 2004-11-18 The Regents Of The University Of California Cyclic bis-compounds clearing malformed proteins
US7320785B2 (en) * 2001-08-10 2008-01-22 The Rockefeller University Compositions and methods for modulation of DARPP-32 phosphorylation
AU2004204814B2 (en) * 2003-01-13 2009-10-08 Cortex Pharmaceuticals, Inc. Method of treating cognitive decline due to sleep deprivation and stress
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
CA2536975A1 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
JP2007519733A (ja) * 2004-01-26 2007-07-19 コーテックス ファーマシューティカルズ インコーポレーティッド アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
US8415298B2 (en) 2004-06-21 2013-04-09 The Board Of Trustees Of The Leland Stanford Junior University Of Stanford Administration of FGF2 for treamtent of anxiety
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
US7396829B2 (en) * 2005-02-24 2008-07-08 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
ME02051B (me) 2005-04-13 2015-05-20 Astex Therapeutics Ltd Derivati hidroksibenzamida i njihova primena kao inhibitora hsp90
KR20060119373A (ko) * 2005-05-20 2006-11-24 엘지전자 주식회사 컴퓨터 시스템과 시스템 소프트웨어 설치방법 및 휴대용컴퓨터의 소프트웨어 설치방법
EP1951908B1 (en) 2005-11-12 2013-08-07 The Board of Trustees of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
WO2007060144A2 (en) * 2005-11-22 2007-05-31 Neurosearch A/S Novel quinoxaline derivatives and their medical use
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US20080176793A1 (en) * 2006-09-18 2008-07-24 The Regents Of The University Of California Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
WO2008044054A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in therapy
JP5410285B2 (ja) 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
EP2073802A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US20090006902A1 (en) * 2007-06-29 2009-01-01 International Business Machines Corporation Methods, systems, and computer program products for reporting fru failures in storage device enclosures
KR20100045507A (ko) 2007-08-10 2010-05-03 코텍스 파마슈티칼스, 인크. 글루타메이트성 시냅스 반응을 향상시키기 위한 비시클릭 아미드
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
JP2012516845A (ja) * 2009-02-02 2012-07-26 コーテックス ファーマシューティカルズ， インコーポレイテッド グルタミン酸作動性シナプス反応を増強するための二環式アミド誘導体
PT105083A (pt) 2009-04-28 2011-07-25 Univ De Coimbra Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
EP2801377B1 (en) 2011-03-04 2019-08-07 The Regents of The University of California Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
EP2854836B1 (en) 2012-06-05 2018-04-04 The Board of Trustees of The Leland Stanford Junior University Ncam peptide mimetic for use in treating major depression disorder
LT3781561T (lt) 2018-04-18 2024-07-10 Constellation Pharmaceuticals, Inc. Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
PE20220562A1 (es) 2019-07-24 2022-04-13 Constellation Pharmaceuticals Inc Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
US5447948A (en) * 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
GB9507230D0 (en) * 1995-04-07 1995-05-31 Inst Of Psychiatry Novel method
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
EP1026950A1 (en) 2000-08-16
JP2001520978A (ja) 2001-11-06
DE69833451D1 (de) 2006-04-20
DE69833451T2 (de) 2006-09-28
CY1105557T1 (el) 2010-07-28
US6166008A (en) 2000-12-26
EP1026950A4 (en) 2004-07-07
WO1999021422A1 (en) 1999-05-06
CA2306817A1 (en) 1999-05-06
AU1365899A (en) 1999-05-17
BR9814106A (pt) 2000-10-03
ES2258825T3 (es) 2006-09-01
AU745641B2 (en) 2002-03-28
HK1030338A1 (en) 2001-05-04
PT1026950E (pt) 2006-06-30
ATE317226T1 (de) 2006-02-15
CN1281335A (zh) 2001-01-24
EP1026950B1 (en) 2006-02-08

Similar Documents

Publication Publication Date Title
DK1026950T3 (da) Behandling af skizofreni med ampakiner og neuroleptika
DE60024588D1 (de) Substituierte porphyrine und deren therapeutische verwendungen
NO2022001I1 (no) Pazopanib
DE69429524D1 (de) Aminocyclohexylester und ihre anwendung
DE69813898D1 (de) Substituierte porphyrinen
AU2002343557A1 (en) Substituted aryl 1,4-pyrazine derivatives
SE9900100D0 (sv) New compounds
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DK0876818T3 (da) Middel til behnadling af nerodegenerative lidelser
JO2359B1 (en) Benzathene derivatives as agents for modulation of GABA A receptor
DK0751939T5 (da) Naphthylamider som centralnervesystemmidler
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
PA8478501A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
DE60025639D1 (de) Substituierte diazepan
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
TW200503717A (en) Substituted 1,4-pyrazine derivatives
TR200200278T2 (tr) Kalsilitik bileşimler
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
NZ511997A (en) Isonipecotamides for the treatment of integrin-mediated disorders
WO2001007431A3 (en) Benzothiophene derivatives
TR200101476T2 (tr) N-ikameli azabisikloaklan türevlerinin merkezi sinir sistemi bozukluklarının tedavisinde kullanılması